Sanofi partners with Innate Pharma on antibody-drug conjugates | Sandoz, Momenta gain FDA approval for generic multiple sclerosis drug | FDA fast-tracks steatohepatitis drug from MediciNova
April 17, 2015
Bio SmartBrief

Today's Top Story
Sanofi partners with Innate Pharma on antibody-drug conjugates
Sanofi and Innate Pharma agreed to collaborate to develop novel antibody drug conjugates using Innate's technology for the conjugation of cytotoxic compounds. Under the terms of the deal, Sanofi will be responsible for assessing payload conjugation to improve the pharmacokinetics of the antibody drug conjugates and will get the option to license the technology with Innate. PharmaTimes (U.K.) (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
Pat Croce Reveals His Insights for Acting on Your Passion
If you're ready to "get your butt off the couch and get into the game of life," it's time to get inspired by this successful entrepreneur and leadership expert. Read the featured article.

Health Care & PolicySponsored By
Sandoz, Momenta gain FDA approval for generic multiple sclerosis drug
Sandoz's and Momenta Pharmaceuticals' Glatopa, the first generic version of multiple sclerosis drug Copaxone from Teva Pharmaceutical, received approval from the FDA. Prescriptions for Copaxone can be switched with Glatopa because the generic will carry the label "substitutable," according to Momenta. Plans to launch the drug were not disclosed. Reuters (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
FDA fast-tracks steatohepatitis drug from MediciNova
The FDA has granted fast-track designation to MediciNova's MN-001, or tipelukast, as a treatment for nonalcoholic steatohepatitis with fibrosis. The agency also gave MediciNova approval to conduct a midstage trial of the drug. San Diego Business Journal (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
New-drug application from Teva, Eagle for blood cancer treatment accepted by FDA
A new-drug application from Teva Pharmaceutical and Eagle Pharmaceuticals for their bendamustine hydrochloride rapid infusion product has been accepted by the FDA. The firms are seeking approval for the drug to be used in patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma who experienced disease progression within six months of rituximab treatment. A decision is expected by December. Pharmaceutical Business Review Online (4/15)
Share: LinkedInTwitterFacebookGoogle+Email
Etanercept biosimilar collaboration agreement amended by Baxter, Coherus
The financial terms of a collaboration agreement for the development and marketing of CHS-0214, a biosimilar of etanercept, in Europe, Canada and several other markets were amended by Coherus BioSciences and Baxter International. In the amended deal, Coherus could receive additional milestone fees of about $12 million, and Baxter will buy common stock from Coherus. Pharmaceutical Business Review Online (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
Hepatitis C drug from AbbVie wins priority review status in Japan
Japan's Ministry of Health, Labour and Welfare has granted priority review to AbbVie's investigational paritaprevir/ritonavir and ombitasvir combination therapy for use in patients with genotype 1 chronic hepatitis C. The priority designation was based on findings of the late-stage GIFT-I trial. PharmaTimes (U.K.) (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
Combating Identity Theft in a Mobile, Social World
Mobile connectivity threats extend from consumers to the business environment. But who is really responsible for securing sensitive information? Smart business leaders are becoming proactive on the matter. Learn how to get protected in this white paper. Download the white paper now.

Company & Financial News
Galapagos targets $150M from IPO
Belgian biotech firm Galapagos, which is developing the rheumatoid arthritis treatment filgotinib, filed for an initial public offering with the goal of raising as much as $150 million. The company expects to receive a licensing deal worth $200 million from AbbVie this year. FierceBiotech (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
Catalent to expand Ky. facility
Catalent Pharma Solutions plans to spend $62 million to expand its facility in Winchester, Ky., to accommodate the demand for oral solid formulations. The firm says the expansion could generate 300 jobs. BioSpace (San Francisco) (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
The Latest From BIO ...
BIO International Convention -- Register Now
BIO 2015 convention
Excitement is building for the largest biotech gathering of the year, and your chance to save on registration ends April 23! Just announced: the BIO 2015 Monday Kickoff Concert featuring Boyz II Men, The Roots and Kool & The Gang. Register at
Share: LinkedInTwitterFacebookGoogle+Email
Food & Agriculture
EU to authorize import of 17 biotech crops
The European Union is set to authorize the import of 17 biotech crops to the country in the following weeks. Biotech crops approved by the European Food Safety Authority are expected to automatically receive authorization based on the proposed new rule on biotech imports. Member states will be given the power to decide on the imports. The Guardian (London) (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
Industrial & Environmental
Report: Biofuel credit price restrictions could aid advanced fuels growth
A new report by Columbia University's Center on Global Energy Policy indicates that limiting the prices of biofuels credits could actually spark growth in the advanced fuels industry. Establishing price caps and floors for Renewable Identification Number prices would remove industry uncertainty over subsidy levels and compliance costs related to the Renewable Fuel Standard, according to James Stock, the author of the report. Reuters (4/16)
Share: LinkedInTwitterFacebookGoogle+Email
News From BIO
BIO International Convention -- Register Now
BIO 2015 convention
The world's largest, most influential biotech meeting is coming to the Pennsylvania Convention Center, June 15-18, 2015, and you won't want to miss it. The BIO International Convention regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development.
  • Face-to-face partnering meetings with thousands of companies
  • Hundreds of Company Presentations from the industry's up-and-coming innovators
  • World-renowned speakers leading Keynote Luncheons and Super Sessions
  • Session tracks covering timely issues in R&D, IP, Business Development, Commercialization, Digital Health, Personalized Medicine and more
  • 1,700+ exhibitors offering a competitive edge in all fields -- from Digital Health and Diagnostics to Bioprocess
  • Exciting networking and social events -- including Monday's Kickoff Concert and Wednesday's Reading Terminal Reception
Join the global biotech community in Philadelphia and see how the everyday becomes extraordinary at BIO 2015. Register now.
Share: LinkedInTwitterFacebookGoogle+Email
Press Releases
Post a Press Release
If you are irritated by every rub, how will your mirror be polished?"
-- Rumi,
poet and theologian
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about BIO ->Conferences | Join Bio | Media | Issues | Industry
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tara Rosenzweig
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information